PEAR
Income statement / Annual
Last year (2022), Pear Therapeutics, Inc.'s total revenue was $12.69 M,
an increase of 201.66% from the previous year.
In 2022, Pear Therapeutics, Inc.'s net income was -$23.74 M.
See Pear Therapeutics, Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
| Period Ended |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
| Operating Revenue |
$12.69 M |
$4.21 M |
$9.38 M |
$32.56 M |
| Cost of Revenue |
$8.18 M
|
$5.23 M
|
$1.72 M
|
$998,000.00
|
| Gross Profit |
$4.51 M
|
-$1.03 M
|
$7.67 M
|
$31.56 M
|
| Gross Profit Ratio |
0.36
|
-0.24
|
0.82
|
0.97
|
| Research and Development Expenses |
$48.31 M
|
$37.04 M
|
$28.08 M
|
$35.70 M
|
| General & Administrative Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Selling, General & Administrative Expenses |
$79.55 M
|
$67.62 M
|
$56.23 M
|
$27.47 M
|
| Other Expenses |
$0.00
|
-$2.05 M
|
-$16.82 M
|
$544,000.00
|
| Operating Expenses |
$127.86 M
|
$104.66 M
|
$84.31 M
|
$63.17 M
|
| Cost And Expenses |
$136.04 M
|
$109.89 M
|
$86.03 M
|
$64.17 M
|
| Interest Income |
$0.00
|
$0.00
|
$0.00
|
$1.42 M
|
| Interest Expense |
$3.89 M
|
$0.00
|
$2.56 M
|
$0.00
|
| Depreciation & Amortization |
-$46.05 M
|
-$46.74 M
|
$1.43 M
|
-$20.10 M
|
| EBITDA |
-$169.40 M |
-$152.43 M |
-$75.22 M |
-$51.70 M |
| EBITDA Ratio |
-13.34
|
-36.22
|
-8.02
|
-1.59
|
| Operating Income Ratio |
-9.72
|
-25.12
|
-8.17
|
-0.97
|
| Total Other Income/Expenses Net |
$47.86 M
|
$40.54 M
|
-$12.17 M
|
$22.27 M
|
| Income Before Tax |
-$75.49 M
|
-$65.14 M
|
-$97.02 M
|
-$9.33 M
|
| Income Before Tax Ratio |
-5.95
|
-15.48
|
-10.34
|
-0.29
|
| Income Tax Expense |
-$51.75 M
|
-$44.85 M
|
$3.56 M
|
-$21.73 M
|
| Net Income |
-$23.74 M
|
-$20.29 M
|
-$100.58 M
|
$12.39 M
|
| Net Income Ratio |
-1.87
|
-4.82
|
-10.72
|
0.38
|
| EPS |
-0.17 |
-0.18 |
-0.73 |
0.0899 |
| EPS Diluted |
-0.17 |
-0.18 |
-0.73 |
0.0899 |
| Weighted Average Shares Out |
$138.71 M
|
$113.33 M
|
$137.80 M
|
$137.80 M
|
| Weighted Average Shares Out Diluted |
$138.71 M
|
$113.33 M
|
$137.80 M
|
$137.80 M
|
| Link |
|
|
|
|
